Cytokine Signalling Forum

Publications





August 19

Eficacia y Seguridad de Peficitinib (ASP015K) en Pacientes con Artritis Reumatoide con Respuesta Inadecuada a Metotrexate: Resultados de un Estudio Fase III Aleatorizado, Doble-Ciego, controlado con Placebo (RAJ4) en Japán

Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Shiomi T, Yamada E, van der Heijde D.
Ann Rheum Dis 2019 DOI: 10.1136/annrheumdis-2019-215164

Peficitinib (PEF) 100 and 150 mg demonstrated robust clinical and structural efficacy in patients with RA who have an inadequate response to MTX. In Japan, two JAK inhibitors, TOF and BARI are currently available for RA patients with an inadequate response to conventional therapies. This randomized phase 3 study (RAJ4), assessed the efficacy and safety of two PEF doses in combination with MTX compared to PBO, in Japanese MTX-IR. Patients were randomized 1:1:1 to PBO, PEF 100 mg and 150 mg with...

Keywords: JAK, Peficitinib, Clinical, Phase 3

Translated by: Igor Koz

February 18

Tofacitinib con Fármacos Modificadores de la Enfermedad Convencionales en Pacientes Chinos con Artritis Reumatoide: Resultados Informados por los Pacientes desde un Ensayo Fase 3 Controlado Aleatorizado

Li Z, An Y, Su H, Li H, Xu J, Zheng Y, Li G, Kwok K, Wang L, Wu Q.
Int J Rheum Dis 2018; 21(2):402–14

This Chinese sub-population of patients with RA from ORAL Sync reported significant improvements in patient-reported outcomes (PROs), which were maintained up to 12 months from tofacitinib (TOF) treatment initiation. ORAL Sync was a randomised, Phase 3 study investigating TOF therapy in combination with csDMARDs in patients with active RA who had previously had an inadequate response to csDMARDs. To date, this is the only Phase 3 study of TOF in patients from China with RA. This analysis inclu...

Keywords: JAK, Tofacitinib, Clinical, PRO

Translated by: Igor Kos